||Last Updated: Nov 17th, 2006 - 22:35:04
Listening to the sound of skin cancer
Researchers at the University of Missouri-Columbia can now detect the spread of skin cancer cells through the blood by literally listening to their sound. The unprecedented, minimally invasive technique causes melanoma cells to emit noise, and could let oncologists spot early signs of metastases -- as few as 10 cancer cells in a blood sample -- before they even settle in other organs.
Oct 17, 2006, 02:06
Malignant melanoma cells secrete a potent embryonic growth factor
A Northwestern University research group has discovered that aggressive melanoma cells secrete Nodal, a protein that is critical to proper embryo formation. The researchers identified the potent and highly unstable embryonic growth factor by injecting aggressive melanoma cells into developing zebrafish embryos, which were used as "biosensors" for tumor cell-derived signals, and were consequently able to induce ectopic (abnormal) embryonic skull and backbone (axes) formation.
Jul 31, 2006, 11:33
New mouse model technology in Melanoma vaccine tool-box
Cancer vaccines are being investigated in early-phase clinical trials around the world, with many of those trials recruiting patients with melanoma. Although tumor regressions have been seen in 10% to 20% of patients with metastatic melanoma, the great promise of cancer vaccines - controlling tumor growth and cancer spread without serious side-effects - remains as yet unrealized. This could be set to change with the publication of a new mouse model technology in Cancer Research, the journal of the American Association of Cancer Research, from a multi-national team led by investigators at the Brussels Branch of the international Ludwig Institute for Cancer Research (LICR).
Mar 28, 2006, 19:44
Malignant melanoma cells reprogrammed !
Scientists at Northwestern University and the Stowers Institute for Medical Research have reprogrammed malignant melanoma cells to become normal melanocytes, or pigment cells, a development that may hold promise in treating of one of the deadliest forms of cancer.
Feb 28, 2006, 17:45
New option for patients with metastatic melanoma
Patients with metastatic melanoma (MM) have new hope, says a recently published study by Mayo Clinic Cancer Center. The study, which shows the combination of paclitaxel and carboplatin (PC) appears to be effective for MM when traditional treatments have failed, is in this month's issue of Cancer
Jan 4, 2006, 05:47
Positive family history increases risk of multiple primary melanomas
Patients with a family history of multiple melanoma skin cancer are at increased risk of multiple primary melanomas, according to a study in the October 5 issue of JAMA.
Oct 6, 2005, 20:47
Role of Slug Gene in Melanoma Metastasis Identified
About 60,000 Americans will be diagnosed with melanoma this year, says the American Cancer Society, and 10,000 of those cases will be fatal. If not caught in the early stages, melanoma can be a particularly virulent form of cancer, spreading through the body with an efficiency that few tumors possess. Now, researchers at Whitehead Institute for Biomedical Research have discovered one of the reasons why this particular skin tumor is so ruthless. Unlike other cancers, melanoma is born with its metastatic engines fully revved.
Sep 6, 2005, 06:36
Incidence Of Nonmelanoma Skin Cancer On The Rise Among Young Adults
A new study from Minnesota finds the incidence of nonmelanoma skin cancer increasing among men and women under the age of 40, according to an article in the August 10 issue of JAMA.
Aug 10, 2005, 22:49
Curcumin - Potent turmeric spice blocks growth of melanoma
Curcumin, the pungent yellow spice found in both turmeric and curry powders, blocks a key biological pathway needed for development of melanoma and other cancers, say researchers from The University of Texas M. D. Anderson Cancer Center.
Jul 12, 2005, 13:13
MITF master regulator is the target of gene amplification in melanoma
Researchers have pinpointed specific gene and protein over-production in metastatic melanoma, pointing the way to a possible new drug target, according to a study published in Nature July 7.
Jul 10, 2005, 15:56
Human Anti-CTLA-4 Antibody in Combination with a gp100 Melanoma Vaccine Shows Significant Benefit in Treating Metastatic Melanoma
Medarex, Inc. ( Nasdaq: MEDX ) and Bristol-Myers Squibb Company ( NYSE: BMY ) announced today that complete or partial responses in seven of 56 patients with metastatic melanoma showed durability ranging from four months to the longest still ongoing at over 34 months, with five of the seven responses ongoing for more than two years.
Apr 25, 2005, 08:06
CR011: An Antibody-Drug Conjugate Shows Durable Effects in Animal Models of Melanoma
CuraGen Corporation (Nasdaq: CRGN - News) announced today that new preclinical data on CR011, one of the oncology products being developed by the Company, were presented at the 96th Annual Meeting of the American Association for Cancer Research in Anaheim, CA. Preclinical data on CR011, an antibody-drug conjugate (ADC) that is expected to enter clinical trials in the first half of 2006, demonstrated that it caused tumor regression in animal xenograft models of melanoma.
Apr 18, 2005, 09:10
New therapy for Advanced Melanoma
Melanoma is a particularly deadly form of skin cancer very resistant to treatment. Researchers at H. Lee Moffitt Cancer Center & Research Institute and the University of South Florida are testing a promising new therapy that prompts the immune system to aid in the fight against melanoma tumors.
Apr 6, 2005, 18:57
Inhibiting Mutant v599EB-Raf protein could Prevent the Spread of Melanoma
Researchers at Penn State College of Medicine have identified the mechanism by which the most mutated gene in melanoma, called v599EB-Raf, aids melanoma tumor development demonstrating its importance as a therapeutic target.
Mar 23, 2005, 19:36
Clinical Trials Tests CpG7909 and Melan-A Combination Melanoma Cancer Vaccines
Results from the first Phase 1 clinical trial of a vaccine composed of a synthetic bacterial sequence, CpG7909 (ProMune TM , Coley Pharmaceuticals), and a melanoma antigen, Melan-A, indicate that this vaccine combination is not only safe but also can improve and bolster immune responses to tumors.
Mar 18, 2005, 16:38